- Home
- WMB vs ZTS Comparison
WMB vs ZTS Comparison
Compare WMB & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WMB | ZTS |
|---|---|---|
| Founded | 1908 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.3B | 48.7B |
| IPO Year | 2002 | 2012 |
Fundamental Metrics
Financial Performance| Metric | WMB | ZTS |
|---|---|---|
| Price | $73.99 | $116.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | $75.50 | ★ $156.20 |
| AVG Volume (30 Days) | ★ 5.2M | 3.4M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.88% | 1.81% |
| EPS Growth | ★ 17.58 | 10.05 |
| EPS | 2.14 | ★ 6.02 |
| Revenue | ★ $11,950,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | $7.03 | $5.69 |
| Revenue Next Year | $10.77 | $4.81 |
| P/E Ratio | $34.03 | ★ $19.56 |
| Revenue Growth | ★ 13.78 | 2.28 |
| 52 Week Low | $51.58 | $114.47 |
| 52 Week High | $76.87 | $172.23 |
Technical Indicators
Market Signals| Indicator | WMB | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 38.21 |
| Support Level | $72.70 | N/A |
| Resistance Level | $76.87 | $130.52 |
| Average True Range (ATR) | 1.45 | 3.23 |
| MACD | -0.47 | -0.69 |
| Stochastic Oscillator | 41.32 | 14.51 |
Price Performance
Historical ComparisonAbout WMB Williams Companies Inc. (The)
Williams operates the Transco pipeline, which connects the Gulf Coast to the Northeast United States. It has additional natural gas transmission pipelines connecting the Rockies to the Pacific Northwest and midcontinent. At the field level, it operates substantial gathering and processing assets in Appalachia and other basins. The company has also struck several power supply agreements.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.